

September 2026 Activities Report and Appendix 4C

Highlights of the Quarter:

- Phase 2a study of PTX-100 in cutaneous T-cell lymphoma (CTCL) reached the pre-specified enrolment threshold for its first planned Dose Optimisation Committee (DOC) review, with 20 evaluable patients – 10 in each of the two dosing arms
- First DOC review on track to convene in December 2026
- Total enrolment of 29 patients at 30 September 2026 (30 June 2026: 26 patients)
- Dr Rosalind Wilson commenced as Chief Medical Officer on 13 July 2026
- Successfully completed a \$6.0 million capital raise, with funds received on 1 October 2026
- Cash balance of \$5.8 million at 30 September 2026, (pro forma \$11.8 million including the proceeds from the \$6.0 million capital raise).
- Join CEO, James McDonnell, for an online investor briefing on Wednesday, 21st October at 11am (AEDT). Register here: <https://prescienttherapeutics.investorportal.com.au/investor-briefing/>

MELBOURNE Australia, 13 October 2026: Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing targeted therapies for cancer, is pleased to provide its Appendix 4C cash flow statement and Activities Report for the quarter ended 30 September 2026. The quarter was marked by the PTX-100 Phase 2a study reaching the enrolment threshold for its first planned Dose Optimisation Committee review, and the successful completion of a \$6 million capital raise.

Share Purchase Plan and Placement

During the quarter, Prescient successfully completed a Share Purchase Plan (SPP), which received continued support from existing shareholders and raised \$4.8 million after final reconciliation, followed by a Placement raising approximately \$1.2 million from sophisticated and professional investors, for a combined raise of approximately \$6.0 million before costs.

The issue price for both the SPP and the Placement was \$0.065 (6.5 cents) per share. Shares were allotted on 30 September 2026. Funds were received on 1 October 2026.

Proceeds will support the advancement of PTX-100 by funding its continued development beyond the first DOC review, scheduled for December 2026, and into the next phase of development.

Financial summary

Prescient ended the quarter with cash reserves of \$5.8 million (June 2026: \$9.03 million). Net operating cash outflows totalled \$3.2 million, including \$1.98 million invested in R&D and clinical activities. The Company received \$6.0 million from the capital raise shortly after the end of the quarter, strengthening the Company's funding position.

Payments to related parties and their associates, being fees payable to non-executive directors, totalled \$80,000.

PTX-100 clinical program

On 2 September 2026, Prescient announced that the Phase 2a study of PTX-100 in relapsed/refractory CTCL had reached the pre-specified enrolment threshold for its first planned DOC review. Ten evaluable patients have been enrolled in each of the study's two dosing arms, 20

evaluable patients in total. Patients are considered evaluable on completion of four cycles of treatment.

The DOC, comprising clinical and biostatistical experts, will convene in December 2026. It will review safety and efficacy data from both dosing arms to provide guidance on continuation of the study for further development, with an update to the market to follow the DOC's recommendation. The December review is a planned milestone in the study's dose optimisation design, not completion of the study.

Three patients were enrolled during the quarter, bringing total enrolment to 29 patients at 30 September 2026. Enrolment during the quarter reflected the seasonal slowdown typical of the Northern Hemisphere summer period, where the majority of the trial's sites are located. Enrolment continues internationally towards the full target of 40 evaluable patients. The trial has sites in Australia, the United States and Italy, and work is progressing to open additional sites in France.

One patient continues to receive PTX-100 on a compassionate access basis, consistent with the clinical response previously observed.

Broader development opportunities

Prescient continues to assess opportunities to generate further clinical data for PTX-100 in Peripheral T-Cell Lymphoma (PTCL). Additional studies will be considered following selection of the recommended Phase 2 dose for CTCL.

Corporate and business development

Dr Rosalind Wilson commenced as Chief Medical Officer on 13 July 2026. Dr Wilson leads Prescient's clinical development strategy and execution, including advancement of PTX-100 through its Phase 2 CTCL study.

The Company continued to progress business development discussions relating to its OmniCAR and CellPryme platforms.

Join a briefing

Join CEO, James McDonnell, for an online investor briefing on Wednesday, 21st October at 11am (AEDT). Register here: <https://prescienttherapeutics.investorportal.com.au/investor-briefing/>

- ENDS -

This announcement has been approved by the Board of Prescient Therapeutics Limited.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor & Media enquiries

Patrick Nelson
Reach Markets
1300 805 795
ir@reachmarkets.com.au



About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100 is a first-in-class compound with the ability to block an enzyme that can contribute to cancer growth known as geranylgeranyl transferase-1 (GGTase-1). Blocking this target disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral signaling circuits in cancer cells, leading to their apoptosis (death). Mutations in Ras pathways are believed to be involved in up to 22% of all cancers.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and in a recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. The Phase 2 study in r/r Cutaneous T-cell lymphoma (CTCL) is recruiting globally. With 20 evaluable patients (10 in each dosing arm) now enrolled, the first Dose Optimisation Committee review will take place in December 2026. Enrolment continues towards the planned 40 evaluable patients.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in preclinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pretreated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via [LinkedIn](#).

Forward Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Prescient Therapeutics Limited

ABN

56 006 569 106

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(1,973)	(1,973)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(658)	(658)
(f) administration and corporate costs	(661)	(661)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	79	79
1.5 Interest and other costs of finance paid	(2)	(2)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(3,215)	(3,215)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(g) entities	-	-
(h) businesses	-	-
(i) property, plant and equipment	-	-

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(j) investments in term deposits with maturities longer than 3 months at acquisition	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments (term deposits)	-	-
	(e) intellectual property	-	-
	(f) Other	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Repayment of lease liability)	(26)	(26)
3.10	Net cash from / (used in) financing activities	(26)	(26)

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	9,028	9,028
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,215)	(3,215)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(26)	(26)
4.5	Effect of movement in exchange rates on cash held	(1)	(1)
4.6	Cash and cash equivalents at end of period	5,786	5,786

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,786	3,028
5.2	Call deposits	4,000	6,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,786	9,028

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	80
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Term Deposits) *	-	4,000
7.4	Total financing facilities	-	4,000
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	* The \$4 million term deposits held by the Company will mature within a month. Hence, they are classified as part of cash and cash equivalents as at 30 September 2026 for accounting purposes.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,215)
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,786
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,786
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	1.80
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Yes. The Company expects net operating cash outflows to remain broadly consistent with recent quarters in the near term, reflecting ongoing PTX-100 development activities undertaken in the ordinary course of business.	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	On 30 September 2026, the Company successfully completed a \$6M capital raise, with funds received on 1 October 2026 (a subsequent event). The capital raise strengthened the Company's liquidity position and provides additional funding for the continued development of PTX-100 beyond the first Dose Optimisation Committee review, scheduled for December 2026.	

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	Yes. Based on the successful completion of the \$6M capital raise referred to in section 8.6.2, the Company believes it has adequate funding to continue the ongoing development of PTX-100 and other operations. Following the quarter end, the Company received \$6M from the capital raise on 1 October 2026 the pro forma value for question 8.5 above is 3.67 quarters.
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 13 October 2026

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.